The human angiotensin AT1 receptor supports G protein-independent extracellular signal-regulated kinase 1/2 activation and cellular proliferation

European Journal of Pharmacology

Volumn 590, Issue 1-3, 2008, Pages 255-263

  Hansen, Jakob Lerche ^a,b,c   Aplin, Mark ^a,b   Hansen, Jonas Tind ^a,b,c   Christensen, Gitte Lund ^a,b,d   Bonde, Marie Mi ^a,b   Schneider, Mikael ^a,e   Haunsø, Stig ^a   Schiffer, Hans H ^c   Burstein, Ethan S ^c   Weiner, David M ^c   Sheikh, Søren P ^a,e  

^a DANISH NATIONAL RESEARCH FOUNDATION   (Denmark)

^b Lab for Molecular Pharmacology   (Denmark)

^c ACADIA PHARMACEUTICALS INC   (United States)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

7TM receptor; Angiotensin; Arrestin; AT1 receptor; Differential activation; GPCR

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN I [5 VALINE]; ANGIOTENSIN II; ANGIOTENSIN II [1 SARCOSINE 4 VALINE 8 ALANINE]; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; ANGIOTENSIN II [1 SARCOSINE 8 LEUCINE]; ANGIOTENSIN II [1 SARCOSINE 8 THREONINE]; ANGIOTENSIN II [1 SARCOSINE]; ANGIOTENSIN II [4 VALINE]; ANGIOTENSIN III; ANGIOTENSIN III [4 VALINE]; ANGIOTENSIN[1-7]; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG INVERSE AGONISM; ENZYME ACTIVATION; GTP-BINDING PROTEINS; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NIH 3T3 CELLS; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION;

EID: 48049099668     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.010     Document Type: Article

References (58)

1. Ahn S., Shenoy S.K., Wei H., and Lefkowitz R.J. Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J. Biol. Chem. 279 (2004) 35518-35525
2. Ahn S., Wei H., Garrison T.R., and Lefkowitz R.J. Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2. J. Biol. Chem. 279 (2004) 7807-7811
3. Aplin M., Christensen G.L., Schneider M., Heydorn A., Gammeltoft S., Kjolbye A.L., Sheikh S.P., and Hansen J.L. The Angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin. Pharmacol. Toxicol. 100 (2007) 289-295
4. Aplin M., Christensen G.L., Schneider M., Heydorn A., Gammeltoft S., Kjolbye A.L., Sheikh S.P., and Hansen J.L. Differential extracellular signal-regulated kinases 1 and 2 activation by the Angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin. Pharmacol. Toxicol. 100 (2007) 296-301
5. Azzi M., Charest P.G., Angers S., Rousseau G., Kohout T., Bouvier M., and Pineyro G. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11406-11411
6. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., and Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 (2005) 261-273
7. Brauner-Osborne H., and Brann M.R. Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells. Eur. J. Pharmacol. 295 (1996) 93-102
8. Burstein E.S., Ma J., Wong S., Gao Y., Pham E., Knapp A.E., Nash N.R., Olsson R., Davis R.E., Hacksell U., Weiner D.M., and Brann M.R. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther. 315 (2005) 1278-1287
9. Burstein E.S., Piu F., Ma J.N., Weissman J.T., Currier E.A., Nash N.R., Weiner D.M., Spalding T.A., Schiffer H.H., Del Tredici A.L., and Brann M.R. Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout. Curr. Pharm. Des. 12 (2006) 1717-1729
10. DeWire S.M., Ahn S., Lefkowitz R.J., and Shenoy S.K. Beta-arrestins and cell signaling. Annu. Rev. Physiol. 69 (2007) 483-510
11. Drake M.T., Violin J.D., Whalen E.J., Wisler J.W., Shenoy S.K., and Lefkowitz R.J. {beta}-Arrestin-biased Agonism at the {beta}2-Adrenergic Receptor. J. Biol. Chem. 283 (2008) 5669-5676
12. Galandrin S., and Bouvier M. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 70 (2006) 1575-1584
13. Ge L., Shenoy S.K., Lefkowitz R.J., and DeFea K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J. Biol. Chem. 279 (2004) 55419-55424
14. Groblewski T., Maigret B., Nouet S., Larguier R., Lombard C., Bonnafous J.C., and Marie J. Amino acids of the third transmembrane domain of the AT1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands. Biochem. Biophys. Res. Commun. 209 (1995) 153-160
15. Groblewski T., Maigret B., Larguier R., Lombard C., Bonnafous J.C., and Marie J. Mutation of Asn111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation. J. Biol. Chem. 272 (1997) 1822-1826
16. Hansen J.L., Servant G., Baranski T.J., Fujita T., Iiri T., and Sheikh S.P. Functional reconstitution of the angiotensin II type 2 receptor and G(i) activation. Circ. Res. 87 (2000) 753-759
17. Hansen J.L., Haunso S., Brann M.R., Sheikh S.P., and Weiner D.M. Loss-of-function polymorphic variants of the human angiotensin II type 1 receptor. Mol. Pharmacol. 65 (2004) 770-777
18. Hansen J.L., Theilade J., Haunsø S., and Sheikh S.P. Oligomerization of wild type and non-functional mutant Angiotensin II type I (AT1) receptors inhibits Gaq protein signaling but not ERK activation. J. Biol. Chem. 279 (2004) 24108-24115
19. Healey J.S., Baranchuk A., Crystal E., Morillo C.A., Garfinkle M., Yusuf S., and Connolly S.J. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 45 (2005) 1832-1839
20. Hines J., Fluharty S.J., and Yee D.K. Structural determinants for the activation mechanism of the angiotensin II type 1 receptor differ for phosphoinositide hydrolysis and mitogen-activated protein kinase pathways. Biochem. Pharmacol. 66 (2003) 251-262
21. Holloway A.C., Qian H., Pipolo L., Ziogas J., Miura S., Karnik S., Southwell B.R., Lew M.J., and Thomas W.G. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol. Pharmacol. 61 (2002) 768-777
22. Hosokawa H., Aiuchi S., Kambe T., Hagiwara Y., and Kubo T. Mechanical stretch-induced mitogen-activated protein kinase activation is mediated via angiotensin and endothelin systems in vascular smooth muscle cells. Biol. Pharm. Bull. 25 (2002) 1588-1592
23. Howes A.L., Miyamoto S., Adams J.W., Woodcock E.A., and Brown J.H. Galphaq expression activates EGFR and induces Akt mediated cardiomyocyte survival: dissociation from Galphaq mediated hypertrophy. J. Mol. Cell. Cardiol. 40 (2006) 597-604
24. Hunton D.L., Barnes W.G., Kim J., Ren X.R., Violin J.D., Reiter E., Milligan G., Patel D.D., and Lefkowitz R.J. Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol. Pharmacol. 67 (2005) 1229-1236
25. Hunyady L., Vauquelin G., and Vanderheyden P. Agonist induction and conformational selection during activation of a G-protein-coupled receptor. Trends Pharmacol. Sci. 24 (2003) 81-86
26. Jensen A.A., Hansen J.L., Sheikh S.P., and Brauner-Osborne H. Probing intermolecular protein-protein interactions in the calcium-sensing receptor homodimer using bioluminescence resonance energy transfer (BRET). Eur. J. Biochem. 269 (2002) 5076-5087
27. Jorgensen R., Holliday N.D., Hansen J.L., Vrecl M., Heding A., Schwartz T.W., and Elling C.E. Characterization of G-protein coupled receptor kinase interaction with the neurokinin-1 receptor using bioluminescence resonance energy transfer. Mol. Pharmacol. 73 (2008) 349-358
28. Kakuta H., Sudoh K., Sasamata M., and Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int. J. Clin. Pharmacol. Res. 25 (2005) 41-46
29. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4 (2005) 919-927
30. Kubo T., Ibusuki T., Chiba S., Kambe T., and Fukumori R. Altered mitogen-activated protein kinase activation in vascular smooth muscle cells from spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 29 (2002) 537-543
31. Le M.T., Vanderheyden P.M., Szaszak M., Hunyady L., Kersemans V., and Vauquelin G. Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors. Biochem. Pharmacol. 65 (2003) 1329-1338
32. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by beta-arrestins. Science 308 (2005) 512-517
33. Lyngbaek S., Schneider M., Hansen J.L., and Sheikh S.P. Cardiac regeneration by resident stem and progenitor cells in the adult heart. Basic Res. Cardiol. 102 (2007) 101-114
34. Mann J.F., Schiller P.W., Schiffrin E.L., Boucher R., and Genest J. Brain receptor binding and central actions of angiotensin analogs in rats. Am. J. Physiol. 241 (1981) R124-129
35. Miserey-Lenkei S., Parnot C., Bardin S., Corvol P., and Clauser E. Constitutive internalization of constitutively active angiotensin II AT(1A) receptor mutants is blocked by inverse agonists. J. Biol. Chem. 277 (2002) 5891-5901
36. Miura S., and Karnik S.S. Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J. Hypertens. 17 (1999) 397-404
37. Miura S., Fujino M., Hanzawa H., Kiya Y., Imaizumi S., Matsuo Y., Tomita S., Uehara Y., Karnik S.S., Yanagisawa H., Koike H., Komuro I., and Saku K. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J. Biol. Chem. 281 (2006) 19288-19295
38. Nanevicz T., Wang L., Chen M., Ishii M., and Coughlin S.R. Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling. J. Biol. Chem. 271 (1996) 702-706
39. Oliveira L., Costa-Neto C.M., Nakaie C.R., Schreier S., Shimuta S.I., and Paiva A.C. The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure. Physiol. Rev. 87 (2007) 565-592
40. Penn R.B., Pascual R.M., Kim Y.M., Mundell S.J., Krymskaya V.P., Panettieri Jr. R.A., and Benovic J.L. Arrestin specificity for G protein-coupled receptors in human airway smooth muscle. J. Biol. Chem. 276 (2001) 32648-32656
41. Premont R.T., and Gainetdinov R.R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 69 (2007) 511-534
42. Rajagopal K., Whalen E.J., Violin J.D., Stiber J.A., Rosenberg P.B., Premont R.T., Coffman T.M., Rockman H.A., and Lefkowitz R.J. Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16284-16289
43. Sen I., Jim K.F., and Soffer R.L. Solubilization and characterization of an angiotensin II binding protein from liver. Eur. J. Biochem. 136 (1983) 41-49
44. Seta K., Nanamori M., Modrall J.G., Neubig R.R., and Sadoshima J. AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J. Biol. Chem. 277 (2002) 9268-9277
45. Szidonya L., Supeki K., Karip E., Turu G., Varnai P., Clark A.J., and Hunyady L. AT1 receptor blocker-insensitive mutant AT1A angiotensin receptors reveal the presence of G protein-independent signaling in C9 cells. Biochem. Pharmacol. 73 (2007) 1582-1592
46. Takayanagi R., Ohnaka K., Sakai Y., Nakao R., Yanase T., Haji M., Inagami T., Furuta H., Gou D.F., Nakamuta M., et al. Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. Biochem. Biophys. Res. Commun. 183 (1992) 910-916
47. Terrillon S., and Bouvier M. Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes. EMBO J. 23 (2004) 3950-3961
48. Theilade J., Lerche Hansen J., Haunso S., and Sheikh S.P. Extracellular signal-regulated kinases control expression of G protein-coupled receptor kinase 2 (GRK2). FEBS Lett. 518 (2002) 195-199
49. Tohgo A., Pierce K.L., Choy E.W., Lefkowitz R.J., and Luttrell L.M. beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation. J. Biol. Chem. 277 (2002) 9429-9436
50. Tohgo A., Choy E.W., Gesty-Palmer D., Pierce K.L., Laporte S., Oakley R.H., Caron M.G., Lefkowitz R.J., and Luttrell L.M. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J. Biol. Chem. 278 (2003) 6258-6267
51. Torella D., Ellison G.M., Nadal-Ginard B., and Indolfi C. Cardiac stem and progenitor cell biology for regenerative medicine. Trends Cardiovasc. Med. 15 (2005) 229-236
52. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B.K., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P., Miller K., Spedding M., and Mailman R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320 (2006) 1-13
53. Wei H., Ahn S., Shenoy S.K., Karnik S.S., Hunyady L., Luttrell L.M., and Lefkowitz R.J. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10782-10787
54. Weiner D.M., Burstein E.S., Nash N., Croston G.E., Currier E.A., Vanover K.E., Harvey S.C., Donohue E., Hansen H.C., Andersson C.M., Spalding T.A., Gibson D.F., Krebs-Thomson K., Powell S.B., Geyer M.A., Hacksell U., and Brann M.R. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 299 (2001) 268-276
55. Wilbanks A.M., Fralish G.B., Kirby M.L., Barak L.S., Li Y.X., and Caron M.G. Beta-arrestin 2 regulates zebrafish development through the hedgehog signaling pathway. Science 306 (2004) 2264-2267
56. Yee D.K., Suzuki A., Luo L., and Fluharty S.J. Identification of structural determinants for G protein-independent activation of mitogen-activated protein kinases in the seventh transmembrane domain of the angiotensin II type 1 receptor. Mol. Endocrinol. 20 (2006) 1924-1934
57. Zaman M.A., Oparil S., and Calhoun D.A. Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov. 1 (2002) 621-636
58. Zhai P., Yamamoto M., Galeotti J., Liu J., Masurekar M., Thaisz J., Irie K., Holle E., Yu X., Kupershmidt S., Roden D.M., Wagner T., Yatani A., Vatner D.E., Vatner S.F., and Sadoshima J. Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/nnnnnnnG alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J. Clin. Invest. 115 (2005) 3045-3056